Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2023-02-28 Regulatory Filings
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated February 28, 2023, announcing a distribution agreement between Advicenne and Avanzanite Bioscience for the commercialization of Sibnayal® across several European countries (Germany, Austria, Switzerland, Greece). This announcement details a strategic partnership concerning product distribution and market access, which falls under corporate or business development news. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it announces a significant business arrangement that impacts future commercial strategy and market presence, it is best classified as a general corporate announcement. Given the provided categories, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard corporate news that doesn't fit the specific financial or governance codes, although 'M&A Activity' (TAR) is related to business deals, this is a distribution agreement, not a merger or takeover. However, RNS serves as the best general category for significant, non-financial press releases.
2023-02-28 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated February 14, 2023, announcing an exclusive distribution agreement between Advicenne and SPA for the commercialization of Sibnayal® in Italy, Spain, and Portugal. This type of announcement details a significant business development, partnership, or strategic move, often related to market expansion or commercial rights. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding business operations and strategy. Since it does not fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Capital Change (CAP), the most appropriate classification is a general Regulatory Filing (RNS), which serves as a broad category for significant corporate news releases that don't have a more specific code, although 'Capital/Financing Update' (CAP) could be considered if the deal involved significant upfront payments or financing terms, but here the focus is on distribution rights and royalties. Given the nature of announcing a major commercial partnership, RNS is the best fit as a general regulatory announcement.
2023-02-14 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated February 14, 2023, announcing an exclusive distribution agreement between Advicenne and SPA for the marketing of Sibnayal® in Italy, Spain, and Portugal. This announcement details a strategic business partnership and commercial development, which falls under the category of corporate actions or significant business updates that are typically released via regulatory channels. Since it is not a formal financial report (like 10-K or IR), an earnings release (ER), a management discussion (MDA), or a specific transaction like a share buyback (POS) or M&A (TAR), it best fits the general category for significant regulatory announcements that don't have a more specific code. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate press release announcing a major commercial agreement, although 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are less relevant. Since it is a formal announcement of a business development, RNS serves as the best general regulatory announcement category.
2023-02-14 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is dated February 1, 2023, and is titled "Advicenne provides an update on its commercial partnerships in Europe and the Middle East." It details operational progress, pricing/reimbursement hurdles in specific countries (Norway, Sweden, Belgium), and early access program setups. This content is characteristic of a press release providing timely operational and commercial updates, often released outside of standard quarterly/annual reporting cycles. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Earnings Release (ER) which focuses on financial figures. It is also not a specific regulatory filing like DIRS or DIV. Since it is a general business update press release that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP), it best fits the general Regulatory Filings category (RNS) as a catch-all for important, non-standard announcements, or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format, RNS is the most appropriate fit among the available options for a general corporate update.
2023-02-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated February 1, 2023, detailing commercial partnership progress, regulatory hurdles (pricing/reimbursement decisions in Nordic countries), and operational updates regarding the drug Sibnayal®. It includes quotes from the CEO and contact information. This format—a formal announcement of business and operational updates, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on commercial progress and partnership milestones rather than just summarizing key financial figures (which would be ER), and it is not a full financial report (10-K, IR), it fits best as a general announcement. Given the content is a business update and not a specific regulatory form like DIRS or DEF 14A, and it is not explicitly announcing the publication of a larger report (RPA), the most appropriate general category for this type of corporate news release is Regulatory Filings (RNS), as it serves as a broad communication to the market about company activities.
2023-02-01 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated February 1, 2023, providing an update on the commercial partnerships and operational progress for the drug Sibnayal® across Europe and the Middle East. It details achievements in specific countries (Norway, Sweden, Belgium) and progress with early access programs. This type of announcement, focusing on business updates, partnership progress, and market access hurdles, is characteristic of an Earnings Release (ER) or a general business update. Since it is not a full annual report (10-K), a formal quarterly report (IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Change (CAP), it best fits the 'Earnings Release' category, which covers initial announcements of periodical performance/business highlights, even if it's not strictly tied to quarterly financials in the title. Given the content focuses on commercial progress and operational milestones, ER is the most appropriate fit among the provided options for a significant business update press release.
2023-02-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.